Viewing Study NCT00003445



Ignite Creation Date: 2024-05-05 @ 11:19 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00003445
Status: COMPLETED
Last Update Posted: 2013-06-26
First Post: 1999-11-01

Brief Title: Docetaxel in Treating Patients With Advanced Cancer of the Cervix
Sponsor: Grupo Oncologico Cooperativo del Sur
Organization: National Cancer Institute NCI

Study Overview

Official Title: Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma
Status: COMPLETED
Status Verified Date: 2001-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of docetaxel in treating patients with advanced cancer of the cervix
Detailed Description: OBJECTIVES I Assess the antitumor activity of docetaxel as neoadjuvant chemotherapy in patients with locally advanced squamous cell carcinoma of the cervix II Assess the tumor response toxic effect and survival rate of this regimen in these patients

OUTLINE Patients receive docetaxel IV over 1 hour on day 1 Treatment is repeated every 3 weeks for 3 courses Patients are followed every 3 months posttreatment

PROJECTED ACCRUAL A total of 16-35 patients will be accrued for this study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-V98-1456 Registry Identifier PDQ Physician Data Query None
CDR0000066473 REGISTRY None None